In 2025, the Gujarat Anti-Terrorism Squad uncovered an alleged ricin-based bioterror plot — India's first suspected ricin-linked bioterrorism case with possible international links. Ricin, a highly toxic protein extracted from castor beans and listed under Schedule-1 of the Chemical Weapons Convention, has no known antidote. Even a few milligrams can be fatal. The Gujarat case was a reminder that biological threats — long treated as theoretical concerns in India's security planning — are now operational realities demanding urgent institutional attention.

India's biosecurity challenge in 2026 is not merely about bioterrorism. It is a multi-dimensional problem spanning state-actor bioweapon threats, non-state actor exploitation of dual-use biology, pandemic preparedness, agricultural biosecurity, and the rapidly evolving risks created by advances in synthetic biology and gene editing. For a country of 1.4 billion people, with one of the world's densest population distributions, a large agricultural economy, and a rapidly growing biotechnology sector, the consequences of a serious biosecurity failure are catastrophic in scale.

The Threat Landscape

India's biosecurity threat environment has three distinct dimensions.

The first is state-sponsored biological warfare. India is aware that its adversaries maintain active programmes in this domain. China's biological warfare capabilities — documented in US intelligence assessments — are the most significant state-level threat. Pakistan's interest in dual-use biological research has been a source of concern for Indian intelligence for decades. Biological weapons are particularly attractive to adversaries with limited conventional military options because they are asymmetric in cost — cheap to produce relative to their potential impact — difficult to attribute, and psychologically devastating.

The second is non-state actor bioterrorism. The Gujarat ricin case illustrates a trend visible globally: non-state actors with limited resources and basic chemistry knowledge can access high-impact biological or toxin agents. The Global Terrorism Index 2025 notes that 93% of fatal attacks in Western countries now involve lone-wolf actors. The same self-radicalisation dynamic that drives lone-wolf kinetic attacks could increasingly drive biological ones — particularly as synthetic biology knowledge becomes more accessible through open-source scientific literature and AI-assisted research tools. India's large population centres, its high-density urban areas, and its dependence on food and water infrastructure that could be targeted through agro-terrorism all create a broad attack surface.

The third is natural pandemic risk amplified by biosafety gaps. India ranked 66th on the Global Health Security Index, with its score for detecting biothreats improving but its score for effective response declining. India's experience of COVID-19 — over 500,000 official deaths, with credible estimates suggesting the true toll was several multiples of that — demonstrated the catastrophic potential of a novel pathogen in a high-density, low-healthcare-spending environment. The risk of another pandemic-scale event, whether natural or engineered, is not theoretical. It is the highest-probability catastrophic biosecurity scenario India faces.

What India Has Built

India's biosecurity infrastructure has expanded significantly in the past five years, driven partly by COVID-19's lessons and partly by a growing awareness of the threat's strategic dimensions.

The most significant recent milestone is the foundation stone laying for India's first state-funded Bio-Safety Level 4 containment facility in Gandhinagar, Gujarat — inaugurated by Home Minister Amit Shah. A BSL-4 facility is the highest level of biological containment, designed to safely handle the world's most dangerous and highly infectious pathogens — including those for which no vaccines or treatments exist. Only approximately 69 BSL-4 laboratories are operational or under development globally. India's NIV in Pune has one; the Gujarat facility will be the country's first state-funded one, significantly expanding India's capacity to research, detect, and develop countermeasures for the most dangerous pathogens.

India's broader laboratory network has also expanded substantially. The Ministry of Health has approved 165 biosafety laboratories under the Virus Research and Diagnostic Laboratories scheme — 154 BSL-2 and 11 BSL-3 labs. ICMR operates 21 biosafety labs across its institutes. An advisory and review committee, formed in November 2024, now oversees the 22 BSL-3 laboratories within the National One Health Mission network, strengthening biosafety standards and pandemic preparedness across the country's containment lab infrastructure.

India's engagement at the 50th anniversary of the Biological Weapons Convention in December 2025 was substantive and forward-leaning. India proposed a National Implementation Framework covering high-risk biological agents, oversight of dual-use research, mandatory domestic reporting, and incident management — and co-proposed an Article VII assistance database with France. India's emphasis on Global South representation in future biosecurity planning reflected a strategic positioning as a credible voice for developing countries in the global biosecurity architecture.

The Structural Gaps India Must Close

India's progress is real. But three structural gaps in its biosecurity architecture remain that demand urgent attention.

The first is the absence of a dedicated national biosecurity agency. India's biosecurity responsibilities are currently fragmented across the Department of Biotechnology, the Ministry of Health, the NDMA, the Agriculture Ministry, and intelligence and security agencies. This fragmentation creates coordination delays, jurisdictional ambiguities, and intelligence sharing gaps that a determined adversary could exploit. The Carnegie Endowment, ORF, and multiple domestic analysts have recommended establishing a nodal Office of Biological Threats Preparedness and Response — a single, empowered agency with cross-ministry authority for both prevention and response. The Gujarat ATS ricin case illustrated exactly the kind of inter-agency coordination challenge that such a body would be designed to address.

The second is legislative modernisation. India's biosecurity legal framework — the Environment Protection Act, the WMD Act of 2005, the Biosafety Rules — was not designed for the synthetic biology, gene editing, and AI-assisted research risks of 2026. Dual-use research governance — ensuring that legitimate biological research does not inadvertently enable weapons development — requires updated legislation and a regulatory framework that keeps pace with the speed of biotechnological innovation. India has yet to develop focal legislation that treats biosecurity as a distinct function from biosafety, and this gap leaves meaningful regulatory space unaddressed.

The third is border and agricultural vulnerability. India shares open or semi-open borders with countries that have significant biosafety gaps of their own. Cross-border movement of people, animals, and agricultural goods creates transmission pathways for both natural and engineered biological threats. Customs officials — currently the primary line of defence against biological imports — are inadequately trained to identify specific pathogens or pests. India's dependence on agriculture makes it particularly vulnerable to agro-terrorism: a pathogen or pest targeting rice, wheat, or livestock could have consequences for food security and rural livelihoods that dwarf the economic impact of most conventional attacks.

The Strategic Imperative

Biosecurity has historically been the neglected dimension of India's national security framework — receiving a fraction of the institutional attention, budget, and strategic thought devoted to conventional and nuclear threats. That calculus must change.

Biological threats are cheap to create, difficult to detect, hard to attribute, and catastrophic in impact. In an era of advancing synthetic biology and increasing non-state actor capability, the biological threat environment India faces in 2036 will be qualitatively more dangerous than the one it faces today. Building the institutional architecture now — the nodal agency, the legislative framework, the laboratory network, the border biosurveillance, and the agricultural biosecurity system — is an investment in preventing threats that would be exponentially more costly to manage after they materialise.

India's pharmaceutical and biotechnology capabilities are world-class. Its scientific talent is among the deepest in the world. The same institutions and human capital that make India the world's pharmacy can, with the right institutional architecture, make India one of the world's most biosecure nations. The investment required is modest relative to the stakes. The urgency is real.

The Hind covers policy, power, and strategic affairs from India's perspective. Views expressed are analytical and editorial.